LYEL - Lyell Immunopharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
LYEL price evolution
LYEL
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $450.05 | $499.82 | $534.16 | $554.69 |
| Long term investments | ||||
| Property, plant & equipment | $124.71 | $130.79 | $136.53 | $142.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $619.22 | $654.14 | $694.22 | $750.03 |
| Current liabilities | ||||
| Accounts payable | $3.6 | $4.2 | $4.89 | $4.82 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $33.51 | $30.88 | $32.35 | $34.52 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $88.52 | $87.64 | $91.06 | $95.08 |
| Shareholders' equity | ||||
| Retained earnings | -$1153.17 | -$1108.59 | -$1062.78 | -$1002.11 |
| Other shareholder equity | $0.76 | -$0.4 | -$0.4 | -$0.09 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $554.69 | $651.29 | $626.29 | $617.55 |
| Long term investments | ||||
| Property, plant & equipment | $142.32 | $166.26 | $166.64 | $124.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $750.03 | $937.56 | $1127.41 | $908.28 |
| Current liabilities | ||||
| Accounts payable | $4.82 | $3.92 | $3.21 | $9.4 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $34.52 | $37.03 | $46.74 | $49.28 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $95.08 | $104.31 | $197.62 | $189.84 |
| Shareholders' equity | ||||
| Retained earnings | -$1002.11 | -$767.48 | $584.36 | $334.14 |
| Other shareholder equity | -$0.09 | -$7.6 | $1.62 | $0.26 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0 | $35.74 | $0.55 | |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $66.44 | $73 | $69.13 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $2.25 | $0.95 | $0.4 | |
| Net income | ||||
| Net income | -$70.25 | -$36.32 | $68.14 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.65 | $0.66 | ||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $225.12 | $102.75 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.91 | $8.12 | ||
| Net income | ||||
| Net income | $250.22 | $129.38 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$58.19 | -$1.1 | $26.12 | $121.57 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $9.77 | $5.01 | $2.56 | $401.24 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$177.7 | -$88.28 | $76.53 | $649.06 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $121.57 | $422.43 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $401.24 | $351.16 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $649.06 | $813.06 | ||
News
Fundamentals
| Market cap | $235.27M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 256.56M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -99.89% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 13.43 |
| Quick ratio | N/A |